Booming Clinical Research Business Could Trigger Regulatory Overhaul In India
This article was originally published in PharmAsia News
Executive Summary
SAN FRANCISCO - Foreign companies could soon get the go-ahead to conduct Phase I studies in India, as part of a national regulatory overhaul spurred on by booming clinical research business, regional experts say